Acute interferon β-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects

被引:41
作者
Goebel, MU
Baase, J
Pithan, V
Exton, MS
Saller, B
Schedlowski, M
Limmroth, V
机构
[1] Univ Essen Gesamthsch, Fac Med, Dept Psychol Med, D-45122 Essen, Germany
[2] Univ Essen Gesamthsch, Dept Med, Div Endocrinol, D-45122 Essen, Germany
[3] Univ Essen Gesamthsch, Fac Med, Dept Neurol, D-45122 Essen, Germany
关键词
interferon beta-1b; side effects; HPA-axis; cytokines; leukocyte distribution;
D O I
10.1016/S0306-4530(01)00099-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It has been suggested that the immune-endocrine communication plays an important role in development and progression of multiple sclerosis (MS). Interferon beta (IFNbeta-1b) treatment is the therapy of choice in patients suffering from relapsing remitting or secondary chronic progressive multiple sclerosis. While typical adverse events of IFNbeta-1b treatment such as flulike symptoms or fatigue are well studied, little is known about the acute changes in the immune and neuroendocrine system. Therefore, we analyzed the short-term effects of IFNbeta-1b on cortisol, epinephrine, norepinephrine, prolactin and growth hormone (GH) plasma levels before and 4, 8 and 24 It after IFNbeta-1b administration in healthy subjects. Moreover, we determined heart rate, blood pressure, body temperature, leukocyte and lymphocyte subsets and plasma levels of interleukin (IL)-1beta, IL-6, IL- 10 and tumor necrosis factor (TNF)-alpha. IFNbeta-1b led to an increase in body temperature and heart rate, and in parallel, elevated cortisol, prolactin and GH plasma levels at 4 and 8 It after IFNbeta-1b injection. There were no significant alterations in blood pressure, norepinephrine or epinephrine plasma levels. Simultaneously, IFNbeta-1b injection led to an immediate granulocytosis while concomitantly decreasing peripheral lymphocytes, especially natural killer (NK) cells. At the same time, IL-6, IL-10 and TNF-alpha plasma levels showed an overall increase. Overall, cytokine administration exerts strong stimulatory effects on the hypothalamic-pituitary-adrenal (HPA)-axis that may contribute to the side effects of IFNbeta-1b therapy and affect the efficacy of IFNbeta-1b treatment. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:881 / 892
页数:12
相关论文
共 31 条
[1]   Immune-neuro-endocrine interactions: Facts and hypotheses [J].
Besedovsky, HO ;
DelRey, A .
ENDOCRINE REVIEWS, 1996, 17 (01) :64-102
[2]   HUMAN FIBROBLAST INTERFERON FOR CLINICAL-TRIALS - PHARMACOKINETICS AND TOLERABILITY IN EXPERIMENTAL-ANIMALS AND HUMANS [J].
BILLIAU, A ;
DESOMER, P ;
EDY, VG ;
DECLERCQ, E ;
HEREMANS, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 16 (01) :56-63
[3]   Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy [J].
Capuron, L ;
Ravaud, A ;
Dantzer, R .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2143-2151
[4]   SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND IMMUNE-MEDIATED INFLAMMATION [J].
CHROUSOS, GP .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20) :1351-1362
[5]   INTERFERON-BETA FOR MULTIPLE-SCLEROSIS [J].
CONNELLY, JF .
ANNALS OF PHARMACOTHERAPY, 1994, 28 (05) :610-616
[6]   Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis [J].
Duddy, ME ;
Armstrong, MA ;
Crockard, AD ;
Hawkins, SA .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 101 (01) :98-109
[7]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[8]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[9]  
Elenkov IJ, 2000, PHARMACOL REV, V52, P595
[10]   Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4 [J].
Furlan, R ;
Bergami, A ;
Lang, R ;
Brambilla, E ;
Franciotta, D ;
Martinelli, V ;
Comi, G ;
Panina, P ;
Martino, G .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 111 (1-2) :86-92